B
Bullisch
Bullisch · 25%NMRA
$1.86
Szenariopreis
$0.487
-0.068 (-13.96%)Zum Schluss
Loading chart…
- Hoch
- 0.568
- Eröffnung
- 0.554
- Volumengewichteter Durchschnittskurs
- 0.51
- Volumen
- 1.65M
- Marktkap.
- 1.47B
- Tief
- 0.461
- Umsatz
- 835.48K
- EV/EBITDA, TTM
- 0.00
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
KI-Analyse of Neumora Therapeutics Inc (NMRA)
KaufenNeumora Therapeutics Inc is a good buy right now due to its recent price increase of 34.99% yesterday and a 5-day change of 26.16%, indicating strong momentum. The RSI is at 68.963, suggesting it is nearing overbought territory but still has room to grow. However, the company has a significant risk with a net loss of $43.1 million reported for Q2 2026, which highlights ongoing financial challenges. Overall, the potential for recovery and upside in the stock price makes it an attractive buy despite the risks.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Neumora Therapeutics Inc (NMRA) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -4.80.
Alphio-AI-Kursszenarien für NMRA
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die NMRA halten
Event-Zeitleiste
News
8.508-31FoolJohnson & Johnson's Investment Portfolio Reveals Biotech Potential
9.508-14NASDAQ.COMNeumora Reports Q2 2026 Financials and Leadership Changes
8.507-27NewsfilterNeumora's NMRA-215 Shows Promising Pre-Clinical Results for Obesity Treatment
8.506-19NASDAQ.COMBiotech Sector Sees FDA Approvals and Layoffs
2.006-17PRnewswireNeumora Therapeutics Faces Stock Collapse After Failed Trials
NMRA FAQ – beantwortet von Alphio AI
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Neumora Therapeutics Inc is a good buy right now due to its recent price increase of 34.99% yesterday and a 5-day change of 26.16%, indicating strong momentum. The RSI is at 68.963, suggesting it is nearing overbought territory but still has room to grow. However, the company has a significant risk with a net loss of $43.1 million reported for Q2 2026, which highlights ongoing financial challenges. Overall, the potential for recovery and upside in the stock price makes it an attractive buy despite the risks.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.